Ayres M - Search Results

1

DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia.

Sexauer AN, Alexe G, Gustafsson K, Zanetakos E, Milosevic J, Ayres M, Gandhi V, Pikman Y, Stegmaier K, Sykes DB. Sexauer AN, et al. Among authors: ayres m. Blood Adv. 2023 Nov 14;7(21):6685-6701. doi: 10.1182/bloodadvances.2023010337. Blood Adv. 2023. PMID: 37648673 Free PMC article.

2

Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells.

Balakrishnan K, Burger JA, Quiroga MP, Henneberg M, Ayres ML, Wierda WG, Gandhi V. Balakrishnan K, et al. Among authors: ayres ml. Blood. 2010 Aug 19;116(7):1083-91. doi: 10.1182/blood-2009-10-246199. Epub 2010 May 4. Blood. 2010. PMID: 20442367 Free PMC article.

3

8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma.

Dennison JB, Shanmugam M, Ayres ML, Qian J, Krett NL, Medeiros LJ, Neelapu SS, Rosen ST, Gandhi V. Dennison JB, et al. Among authors: ayres ml. Blood. 2010 Dec 16;116(25):5622-30. doi: 10.1182/blood-2010-05-285866. Epub 2010 Sep 15. Blood. 2010. PMID: 20844237 Free PMC article.

4

Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells.

El-Mabhouh AA, Ayres ML, Shpall EJ, Baladandayuthapani V, Keating MJ, Wierda WG, Gandhi V. El-Mabhouh AA, et al. Blood. 2014 Jun 12;123(24):3780-9. doi: 10.1182/blood-2013-12-541433. Epub 2014 Apr 18. Blood. 2014. PMID: 24747434 Free PMC article.

5

Ex Vivo Pharmacological Profiling in Chronic Lymphocytic Leukemia Cells.

Aslan B, Ayres ML, Gandhi V. Aslan B, et al. Methods Mol Biol. 2019;1881:19-25. doi: 10.1007/978-1-4939-8876-1_2. Methods Mol Biol. 2019. PMID: 30350194

6

Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP.

Balakrishnan K, Stellrecht CM, Genini D, Ayres M, Wierda WG, Keating MJ, Leoni LM, Gandhi V. Balakrishnan K, et al. Among authors: ayres m. Blood. 2005 Jun 1;105(11):4455-62. doi: 10.1182/blood-2004-05-1699. Epub 2005 Feb 17. Blood. 2005. PMID: 15718423 Free PMC article.

7

Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia.

Gandhi V, Plunkett W, Du M, Ayres M, Estey EH. Gandhi V, et al. Among authors: ayres m. J Clin Oncol. 2002 Feb 1;20(3):665-73. doi: 10.1200/JCO.2002.20.3.665. J Clin Oncol. 2002. PMID: 11821446 Clinical Trial.

8

A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).

Gandhi V, Kilpatrick JM, Plunkett W, Ayres M, Harman L, Du M, Bantia S, Davisson J, Wierda WG, Faderl S, Kantarjian H, Thomas D. Gandhi V, et al. Among authors: ayres m. Blood. 2005 Dec 15;106(13):4253-60. doi: 10.1182/blood-2005-03-1309. Epub 2005 Aug 30. Blood. 2005. PMID: 16131572 Free PMC article. Clinical Trial.

9

PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells.

Cervantes-Gomez F, Stellrecht CM, Ayres ML, Keating MJ, Wierda WG, Gandhi V. Cervantes-Gomez F, et al. Among authors: ayres ml. Oncotarget. 2019 Apr 19;10(29):2793-2809. doi: 10.18632/oncotarget.26876. eCollection 2019 Apr 19. Oncotarget. 2019. PMID: 31073371 Free PMC article.

10

Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia.

Yi X, Jain N, Iles LR, Ayres ML, Wierda WG, Gandhi V. Yi X, et al. Front Oncol. 2022 Feb 22;12:833714. doi: 10.3389/fonc.2022.833714. eCollection 2022. Front Oncol. 2022. PMID: 35273915 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

225 results

Search Page

Filters